Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2023 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Nov 11, 2022
Slide 1: Investor Presentation Q2FY23
Investor Presentation Q2FY23 November 11, 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q2FY23
Key Highlights of Q2FY23 • Revenue from Operations grew by 10.0% YoY during the quarter, with EBITDA margin of 14.7% and Net Profit margin of 10.7% • India Business: As per IQVIA,Company’s sales in Q2FY23 registered growth of 13.2% YoY compared to IPM growth of 8.2% YoY • Market beating performance
Slide 4: Key Financial Highlights – Q2FY23 (Consolidated)
Key Financial Highlights – Q2FY23 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 22,161 19,605 30,793 28,000 QFY22 Q2FY23 International sales 8,052 8,291 Q2FY22 QFY23 Q2FY22 Q2FY23
Slide 5: Key Financial Highlights – Q2FY23 (Consolidated)
Key Financial Highlights – Q2FY23 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 17,425 17,724 6,244 4,539 62.2% 57.6% 22.3% 14.7% Q2FY22 Q2FY23 Q2FY22 Q2FY23 PBT (before Minority Interest) PAT (after Minority Interest) 5,443 5,815 3,308 4,023 Q2FY22 Q2FY23
Slide 6: Key Financial Highlights – H1FY23 (Consolidated)
Key Financial Highlights – H1FY23 (Consolidated) All figures in ₹ mn Particulars (₹ mn) H1FY23 H1FY22 YoY growth Revenue from Operations 56,558 55,314 2.2% Gross Profit 32,534 33,791 -3.7% Gross Profit margin 57.5% 61.1% EBITDA 6,572 12,172 -46.0% EBITDA margin 11.6% 22.0% PBT 5,542 11,377 -51.3% PB
Slide 7: India Business
India Business India Business: Q2FY23 Sales of ₹ 22,161 million (13.0% YoY growth) • India sales contributed 72.8% to total sales in Q2FY23 • As per IQVIA, In Q2FY23, the Company’s secondary sales grew by 13.2% compared to IPM growth of 8.2% YoY. • Outperformance in acute therapies was mainly led by
Slide 8: Secondary Sales Performance
Secondary Sales Performance Market beating performance across major therapeutic segments in Q2FY23 Market rank 1 3 3 2 Acute Therapies Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients 22.7% 19.2% 12.5% 11.6% 11.5% 7.8% 7.2% 6.4% Alkem sales growth YoY1,2 Indian pharm
Slide 9: US Business
US Business US Business: Q2FY23 Sales of ₹ 6,040 million (YoY decline of 0.9%) • US sales contributed 19.8% to total sales in Q2FY23 • During the quarter, the US business registered sequential growth of 8.5% over Q1FY23 • In Q2FY23, the Company filed 3 ANDAs with the US FDA and received 4 approvals
Slide 10: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Received 1 observation. The Company has already submitted a detailed Indore Formulations July 2022 response to the US FDA on the corrective and preventive actions it is taking to address them. Re
Slide 11: Other International Business
Other International Business Other International Business: Q2FY23 Sales of ₹ 2,251 million (15.2% YoY growth) • Other International Market sales contributed 7.4 % to total sales in Q2FY23 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Key markets li
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2022 Non-Institution, 22.65% Promoter & Promoter Group, 57.16% Institution, 20.19% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 13: Thank You
Thank You For further information or queries, please contact Amit Kumar Khandelia AVP Finance Tel: +91 22 3982 9999 E-mail: amit.khandelia@alkem.com